

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM425446

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Deutsche Bank AG New York Branch		04/27/2017	Bank: GERMANY
RECEIVING PARTY DATA			
Name:	Endo Global Ventures (for itself and as successor to Auxilium US Holdings, LLC)		
Street Address:	Canon's Court, 22 Victoria Street		
City:	Hamilton		
State/Country:	BERMUDA		
Postal Code:	HM 12		
Entity Type:	Unlimited Liability Company: BERMUDA		
Name:	Auxilium International Holdings, LLC (formerly known as Auxilium International Holdings, Inc.)		
Street Address:	1400 Atwater Drive		
City:	Malvern		
State/Country:	PENNSYLVANIA		
Postal Code:	19355		
Entity Type:	Limited Liability Company: DELAWARE		
Name:	Actient Pharmaceuticals LLC (for itself and as successor to Actient Holdings LLC)		
Street Address:	1400 Atwater Drive		
City:	Malvern		
State/Country:	PENNSYLVANIA		
Postal Code:	19355		
Entity Type:	Limited Liability Company: DELAWARE		
Name:	Slate Pharmaceuticals, LLC (formerly known as Slate Pharmaceuticals, Inc.)		
Street Address:	1400 Atwater Drive		
City:	Malvern		
State/Country:	PENNSYLVANIA		
Postal Code:	19355		
Entity Type:	Limited Liability Company: DELAWARE		
Name:	Actient Therapeutics LLC		

CH \$865.00 4392463

Street Address:	1400 Atwater Drive
City:	Malvern
State/Country:	PENNSYLVANIA
Postal Code:	19355
Entity Type:	Limited Liability Company: DELAWARE
Name:	70 Maple Avenue, LLC
Street Address:	1400 Atwater Drive
City:	Malvern
State/Country:	PENNSYLVANIA
Postal Code:	19355
Entity Type:	Limited Liability Company: DELAWARE
Name:	Auxilium Pharmaceuticals, LLC (formerly known as Auxilium Pharmaceuticals, Inc.)
Street Address:	1400 Atwater Drive
City:	Malvern
State/Country:	PENNSYLVANIA
Postal Code:	19355
Entity Type:	Limited Liability Company: DELAWARE

PROPERTY NUMBERS Total: 34

Property Type	Number	Word Mark
Registration Number:	4392463	ACTIENT
Registration Number:	4165007	ACTIENT
Registration Number:	4187212	ACTIENT PHARMACEUTICALS
Registration Number:	4392464	ACTIENT PHARMACEUTICALS
Registration Number:	1151441	DILATRATE
Registration Number:	2177234	EDEX
Registration Number:	1392091	LEVATOL
Registration Number:	3023249	SEMPREX
Registration Number:	2795914	STRIANT
Registration Number:	1259784	THEO-24
Registration Number:	4098455	YOUROLOGY
Registration Number:	2767622	TESTIM
Registration Number:	3637033	HANDSURGERYNEWS.COM
Registration Number:	4410839	ASK ABOUT THE CURVE
Registration Number:	2754314	AUXILIUM
Registration Number:	3333304	AUXILIUM
Registration Number:	3409698	AUXILIUM INNOVATIONS FOR LIFE
Registration Number:	3409699	INNOVATIONS FOR LIFE
Registration Number:	4648524	VIA PROJECT

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	3785074	XIAFLEX
Registration Number:	3886633	XIAFLEX
Registration Number:	3862018	XIAFLEX COLLAGENASE CLOSTRIDIUM HISTOLYT
Registration Number:	4010231	XIAFLEX COLLAGENASE CLOSTRIDIUM HISTOLYT
Registration Number:	4531835	XIAFLEX LINX
Registration Number:	3884247	XIAFLEX XPERIENCE
Registration Number:	4418066	A?K ABOUT THE CURVE
Registration Number:	1089034	TESTOPEL
Registration Number:	1089033	ESTRAPEL
Serial Number:	86377183	AUXILIUM ADVANTAGE
Serial Number:	86377210	AUXILIUM ADVANTAGE COMMITTED TO ACCESS
Serial Number:	85857689	ERIPLAQ
Serial Number:	85857715	PEYROMIN
Serial Number:	86459962	THIS TIME HE WAS READY
Serial Number:	85857741	XIAVANCE

CORRESPONDENCE DATA

Fax Number: 2127352000
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Phone: 212-735-2811
Email: mribando@skadden.com
Correspondent Name: Skadden, Arps, Slate, Meagher & Flom LLP
Address Line 1: Four Times Square
Address Line 2: Monique L. Ribando
Address Line 4: NEW YORK, NEW YORK 10036

ATTORNEY DOCKET NUMBER:	036890/15
NAME OF SUBMITTER:	Oren Epstein
SIGNATURE:	/OE/
DATE SIGNED:	04/28/2017

Total Attachments: 8
source=Exec Trademark Release 2017(Jan 2015)#page1.tif
source=Exec Trademark Release 2017(Jan 2015)#page2.tif
source=Exec Trademark Release 2017(Jan 2015)#page3.tif
source=Exec Trademark Release 2017(Jan 2015)#page4.tif
source=Exec Trademark Release 2017(Jan 2015)#page5.tif
source=Exec Trademark Release 2017(Jan 2015)#page6.tif
source=Exec Trademark Release 2017(Jan 2015)#page7.tif
source=Exec Trademark Release 2017(Jan 2015)#page8.tif

RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS (this “**Release**”), dated as of April 27, 2017, is made by and from DEUTSCHE BANK AG NEW YORK BRANCH, for itself and as Collateral Agent for the Secured Parties (in such capacities, the “**Assignor**”), to and in favor of Endo Global Ventures (for itself and as successor to Auxilium US Holdings, LLC), Auxilium International Holdings, LLC (formerly known as Auxilium International Holdings, Inc.), Actient Pharmaceuticals LLC (for itself and as successor to Actient Holdings LLC), Slate Pharmaceuticals, LLC (formerly known as Slate Pharmaceuticals, Inc.), Actient Therapeutics LLC, 70 Maple Avenue, LLC, and Auxilium Pharmaceuticals, LLC (formerly known as Auxilium Pharmaceuticals, Inc.) (the “**Assignees**”).

W I T N E S S E T H:

WHEREAS, the Assignees and the Assignor are parties to (i) that certain US Pledge and Security Agreement, dated as of February 28, 2014, (ii) that certain Guaranty, dated as of February 28, 2014 and (iii) that certain Confirmatory Grant of Security Interest in United States Trademarks, dated as of January 29, 2015 (the “**Trademark Security Agreement**”);

WHEREAS, pursuant to the Trademark Security Agreement, the Assignees pledged and granted to the Assignor, on behalf of and for the benefit of the Secured Parties, a security interest in all of each of the Assignee’s right, title and interest, wherever located and whether then owned or thereafter acquired in and to (collectively, the “**Trademark Collateral**”):

- (a) its trademarks (including service marks), trade names, trade styles, trade dress, and the registrations and applications for registration thereof, including those listed on Schedule I attached hereto, and the goodwill of the business symbolized by the foregoing; (collectively, the “**Trademarks**”);
- (b) all renewals of the foregoing;
- (c) all rights to sue for past, present and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing;
- (d) all income, royalties, damages, claims and payments then or thereafter due or payable with respect thereto, including, without limitation, damages, claims and payments for past and future infringements thereof); and
- (e) all rights corresponding to any of the foregoing throughout the world.

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on February 4, 2015 at Reel/Frame No. 5453/0246; and

WHEREAS, the Assignees desire that the Assignor terminate, release and discharge fully its security interest the Trademark Collateral.

NOW THEREFORE, in consideration of the premises, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor agrees as follows:

SECTION 1. Defined Terms. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Trademark Security Agreement.

SECTION 2. Termination and Release. The Assignor hereby terminates, releases and discharges fully, without representation or warranty, its security interest in and to the Trademark Collateral, including the Trademarks listed on Schedule I attached hereto, and reassigns and transfers to the Assignees all right, title and interest that the Assignor may have in the Trademark Collateral.

SECTION 3. Recordation. The Assignor hereby authorizes the Assignees, or the Assignees' authorized representatives, to record this Release with the United States Patent and Trademark Office.

SECTION 4. Further Assurances. The Assignor hereby agrees to duly execute and deliver to the Assignees any further documents and to do such other acts that the Assignees (or their respective agents or designees) reasonably request, at the Assignees' sole cost and expense, in order to confirm this Release and the Assignees' right, title and interest in the Trademark Collateral.

SECTION 5. Governing Law. THIS RELEASE SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.

[Signature Page Follows]

IN WITNESS WHEREOF, the Assignor has caused this Release to be executed and delivered by their respective duly authorized officers as of the date first set forth above.

DEUTSCHE BANK AG NEW YORK
BRANCH, as Assignor

By: Peter Cucchiara

Name:

Peter Cucchiara

Title:

Vice President

By: Dusan Lazarov

Name:

Dusan Lazarov

Director

Title:

IN WITNESS WHEREOF, the Assignor and Assignees have caused this Release to be executed and delivered by their respective duly authorized officers as of the date first set forth above.

70 MAPLE AVENUE, LLC, as Assignee

By: ACTIENT PHARMACEUTICALS LLC, as
its Manager

By: AUXILIUM PHARMACEUTICALS,
LLC, as its Manager

By: 
Name: Deanna Voss
Title: Assistant Secretary

ACTIENT THERAPEUTICS LLC, as Assignee


By: 
Name: Deanna Voss
Title: Assistant Secretary

ACTIENT PHARMACEUTICALS LLC (for itself and
as successor to Actient Holdings LLC)
AUXILIUM US HOLDINGS, LLC
each, as Assignee


By: AUXILIUM PHARMACEUTICALS, LLC, as
its Manager

By: 
Name: Deanna Voss
Title: Assistant Secretary


AUXILIUM PHARMACEUTICALS, LLC (formerly known as Auxilium Pharmaceuticals, Inc.), as Assignee

By: 
Name: Deanna Voss
Title: Assistant Secretary

AUXILIUM INTERNATIONAL HOLDINGS, LLC (formerly known as Auxilium International Holdings, Inc.), as Assignee

By: 
Name: Deanna Voss
Title: Assistant Secretary

SLATE PHARMACEUTICALS, LLC (formerly known as Slate Pharmaceuticals, Inc.), as Assignee

By: 
Name: Deanna Voss
Title: Assistant Secretary

ENDO GLOBAL VENTURES, as Assignee

By: 

Name: Robert J. Cobuzzi

Title: Director

[Signature Page - Trademark Release]

TRADEMARK
REEL: 006045 FRAME: 0713

SCHEDULE I
to
RELEASE OF SECURITY INTEREST IN TRADEMARKS

TRADEMARK REGISTRATIONS AND TRADEMARK APPLICATIONS

Trademark	Country	App. No.	App. Date	Reg. No.	Reg. Date	Owner
ACTIENT	United States	77/684,171	3 /5 /2009	4392463	8 /27/2013	Actient Pharmaceuticals LLC
ACTIENT	United States	77/983,129	3 /5 /2009	4165007	6 /26/2012	Actient Pharmaceuticals LLC
ACTIENT PHARMACEUTICA LS	United States	77/983,131	3 /5 /2009	4187212	8 /7 /2012	Actient Pharmaceuticals LLC
ACTIENT PHARMACEUTICA LS	United States	77/684,190	3 /5 /2009	4392464	8 /27/2013	Actient Pharmaceuticals LLC
DILTRATE	United States	73/225,986	8 /3 /1979	1151441	4 /21/1981	Actient Pharmaceuticals LLC
EDEX	United States	75/089,727	4 /17/1996	2177234	7 /28/1998	Actient Pharmaceuticals LLC
LEVATOL	United States	73/558,642	9 /16/1985	1392091	5 /6 /1986	Actient Pharmaceuticals LLC
SEMPREX	United States	78/429,596	6 /3 /2004	3023249	12/6 /2005	Actient Pharmaceuticals LLC
STRIANT	United States	76/442,855	8 /19/2002	2795914	12/16/2003	Actient Pharmaceuticals LLC
THEO-24	United States	73/369,262	6 /14/1982	1259784	12/6 /1983	Actient Pharmaceuticals LLC
YOUROLOGY	United States	85/331,274	5 /26/2011	4098455	2 /14/2012	Actient Pharmaceuticals LLC
TESTIM	United States	76/310,800	9 /7 /2001	2767622	9 /23/2003	Auxilium Pharmaceuticals, Inc.
HANDSURGERYNE WS.COM (Stylized)	United States	77/528,060	7 /22/2008	3637033	6 /9 /2009	Auxilium US Holdings, LLC
ASK ABOUT THE CURVE	United States	85/858,684	2 /25/2013	4410839	10/1 /2013	Endo Global Ventures
AUXILIUM	United States	76/975,483	8 /15/2000	2754314	8 /19/2003	Auxilium US Holdings, LLC.
AUXILIUM & Design	United States	76/673,677	3 /5 /2007	3333304	11/13/2007	Auxilium US Holdings, LLC.
AUXILIUM ADVANTAGE	United States	86/377,183	8 /26/2014			Auxilium US Holdings, LLC.
AUXILIUM ADVANTAGE COMMITTED TO ACCESS & Design	United States	86/377,210	8 /26/2014			Auxilium US Holdings, LLC.

[Schedule I to Release of Security Interest in Trademarks]

Trademark	Country	App. No.	App. Date	Reg. No.	Reg. Date	Owner
AUXILIUM INNOVATIONS FOR LIFE	United States	76/673,067	2 /23/2007	3409698	4 /8 /2008	Auxilium US Holdings, LLC.
ERIPLAQ	United States	85/857,689	2 /22/2013			Auxilium US Holdings, LLC.
INNOVATIONS FOR LIFE	United States	76/673,068	2 /23/2007	3409699	4 /8 /2008	Auxilium US Holdings, LLC.
PEYROMIN	United States	85/857,715	2 /22/2013			Auxilium US Holdings, LLC.
THIS TIME HE WAS READY	United States	86/459,962	11/20/2014			Auxilium US Holdings, LLC.
VIA PROJECT & Design	United States	86/247,222	4 /9 /2014	4648524	12/2 /2014	Auxilium US Holdings, LLC.
XIAFLEX	United States	76/665,957	9 /13/2006	3785074	5 /4 /2010	Endo Global Ventures.
XIAFLEX (Stylized)	United States	77/274,256	9 /7 /2007	3886633	12/7 /2010	Endo Global Ventures
XIAFLEX COLLAGENASE CLOSTRIDIUM HISTOLYTICUM & Design	United States	77/883,942	12/2 /2009	3862018	10/12/2010	Endo Global Ventures
XIAFLEX COLLAGENASE CLOSTRIDIUM HISTOLYTICUM TRANSFORMING TREATMENT & Design	United States	85/036,497	5 /12/2010	4010231	8 /9 /2011	Endo Global Ventures
XIAFLEX LINX	United States	85/856,083	2 /21/2013	4531835	5 /20/2014	Endo Global Ventures
XIAFLEX XPERIENCE &	United States	77/910,711	1 /13/2010	3884247	11/30/2010	Endo Global Ventures
XIAVANCE	United States	85/857,741	2 /22/2013			Auxilium US Holdings, LLC.
ASK ABOUT THE CURVE & Design	United States	85/858,703	2 /25/2013	4418066	10/15/2013	Endo Global Ventures
TESTOPEL	United States	73/132,009	6 /27/1977	1089034	4 /11/1978	Slate Pharmaceuticals, Inc.
ESTRAPEL	United States	73/132,008	6 /27/1977	1089033	4 /11/1978	Slate Pharmaceuticals, Inc. .